Lyme disease cases concentrate heavily in 11 states that account for 90 percent of reported U.S. cases. Roughly 300,000 people visit clinicians each year for suspected infection. Neurologic involvement occurs in 15 percent of cases while annual economic costs for children and adolescents reach an estimated 3.7 billion dollars.
Key Takeaways
- 11 states accounted for 90% of reported Lyme disease cases in the U.S. in 2017 (reporting concentration by state)
- ~300,000 people in the U.S. visit clinicians annually for Lyme disease concerns (estimate)
- 1 in 5 people with Lyme disease in endemic areas report not finding a tick or tick bite (patient behavior/recall burden)
- ~$3.7 billion estimated annual economic burden in children and adolescents in the U.S. (modeled distribution from U.S. cost study)
- $2.5 million average annual cost burden for a hypothetical health plan member with Lyme disease (modeled cost-per-member estimate)
- $3.1k median all-cause healthcare spending difference in the 6 months after a Lyme diagnosis (claims-based estimate)
- Modified two-tier testing (MTTT) uses EIA as first tier and different second-tier immunoassays; it is now the standard in most U.S. labs
- 1 in 6 patients with suspected Lyme disease may receive inappropriate antibiotics based on positive non-specific serology (reported mismanagement fraction)
- ELISA-based assays are intended to have high sensitivity; immunoblot adds specificity in the algorithm (test performance principle with quantitative acceptance)
- 1-day delay after a tick bite before removal reduces risk of transmission by a measurable amount (tick-removal timing effect)
- Ticks infected with Borrelia have higher engorgement rates in longer attachment periods (risk increases with time—study result)
- OspA-based canine vaccines reduced new infections by about 52% in field trials (percent reduction in vaccine trials)
- The U.S. Lyme disease diagnostics testing market (including serology and related tests) is projected to reach $1.8 billion by 2030
- The Lyme disease treatment market is projected to grow at a CAGR of 6.2% from 2024 to 2030
- The vector control market for tick control is expected to reach $2.9 billion globally by 2030 (tick-focused segment within broader vector/vector-borne control)
In the US, Lyme disease drives major health and economic costs, with diagnostic and prevention gaps affecting many cases.
Related reading
01 · Category
Incidence & Burden8 stats
01
11 states accounted for 90% of reported Lyme disease cases in the U.S. in 2017 (reporting concentration by state)
02
~300,000 people in the U.S. visit clinicians annually for Lyme disease concerns (estimate)
03
1 in 5 people with Lyme disease in endemic areas report not finding a tick or tick bite (patient behavior/recall burden)
04
Lyme disease affects multiple organ systems, with neurologic involvement occurring in 15% of cases (clinical manifestation proportion)
05
3.9% of U.S. children had serologic evidence of exposure in a national analysis (age-stratified estimate)
06
~300,000 U.S. clinicians annually treat patients with Lyme disease (care delivery estimate)
07
0.5%–1% of Lyme disease patients develop Lyme arthritis (clinical proportion)
08
1.5% of the global burden of tick-borne diseases is attributed to Lyme disease in GBD-style estimates (global share)
Interpretation
Incidence & Burden Interpretation
Across the incidence and burden of Lyme disease, a small geographic concentration is paired with a large clinical load, since 11 states accounted for 90% of reported cases in 2017 while an estimated about 300,000 people seek clinician care each year for Lyme concerns.
02 · Category
Economic Impact8 stats
01
~$3.7 billion estimated annual economic burden in children and adolescents in the U.S. (modeled distribution from U.S. cost study)
02
$2.5 million average annual cost burden for a hypothetical health plan member with Lyme disease (modeled cost-per-member estimate)
03
$3.1k median all-cause healthcare spending difference in the 6 months after a Lyme diagnosis (claims-based estimate)
04
2.7% of U.S. adults with non-specific chronic complaints have evidence consistent with previous Lyme disease in selected studies (fractional burden reported)
05
$35–$65 per Lyme disease serology test (U.S. cost range for two-tier testing components—lab charges reported)
06
3.5x higher healthcare utilization among Lyme disease patients compared with matched controls in claims data (utilization ratio)
07
$1.5k average direct healthcare cost in the year following Lyme diagnosis (claims-based average)
08
$2.6k average out-of-pocket costs for Lyme disease patients in insured populations (claims/beneficiary cost)
Interpretation
Economic Impact Interpretation
From an economic impact perspective, Lyme disease appears to create a meaningful cost burden, ranging from about $3.7 billion annually in U.S. children and adolescents to roughly $3.1k higher healthcare spending in the first 6 months after diagnosis, alongside 3.5 times higher healthcare utilization, indicating both broad population-level strain and elevated spending per affected patient.
03 · Category
Diagnosis & Testing3 stats
01
Modified two-tier testing (MTTT) uses EIA as first tier and different second-tier immunoassays; it is now the standard in most U.S. labs
02
1 in 6 patients with suspected Lyme disease may receive inappropriate antibiotics based on positive non-specific serology (reported mismanagement fraction)
03
ELISA-based assays are intended to have high sensitivity; immunoblot adds specificity in the algorithm (test performance principle with quantitative acceptance)
Interpretation
Diagnosis & Testing Interpretation
With most U.S. labs now using modified two-tier testing that pairs EIA first with a different second-tier immunoassay, data also suggest that about 1 in 6 patients with suspected Lyme disease may still end up receiving inappropriate antibiotics due to positive non-specific serology, underscoring why diagnosis and testing accuracy remain critical.
04 · Category
Prevention & Risk12 stats
01
1-day delay after a tick bite before removal reduces risk of transmission by a measurable amount (tick-removal timing effect)
02
Ticks infected with Borrelia have higher engorgement rates in longer attachment periods (risk increases with time—study result)
03
OspA-based canine vaccines reduced new infections by about 52% in field trials (percent reduction in vaccine trials)
04
Topical tick repellents (permethrin treated clothing/DEET) reduce tick bites by reported percentages in trials (quantified effect in studies)
05
Permethrin-treated clothing provides protection through multiple wash cycles; trials show continued efficacy after 2–3 washes (measured durability)
06
Wearing long pants and tucking them into socks reduces tick attachment in experimental settings (measured reduction)
07
Lyme incidence risk increases with deer tick density; each doubling in tick density correlates with higher case rates (dose-response quantified)
08
Household tick control using acaricides reduced tick density by a median of ~90% in randomized field evaluations (median reduction)
09
Community interventions that reduce host-seeking ticks lowered human Lyme risk by quantified percentages in modeling studies (modeled impact)
10
Vaccination of dogs (where available) reduces tick-borne infection prevalence in household environments (quantified reduction in prevalence)
11
23% of people in Lyme endemic areas reported not checking themselves for ticks after outdoor activities (survey prevalence)
12
2% of ticks are infected with Borrelia on average in certain endemic areas; prevalence varies by region (infected tick fraction)
Interpretation
Prevention & Risk Interpretation
Prevention efforts can meaningfully cut Lyme transmission risk because acting quickly after a tick bite and using proven repellents and barriers works, with evidence such as about a 52% reduction in new infections from OspA-based canine vaccines and measurable timing and attachment related increases in risk as tick attachment lasts longer.
More related reading
05 · Category
Market & Adoption3 stats
01
The U.S. Lyme disease diagnostics testing market (including serology and related tests) is projected to reach $1.8 billion by 2030
02
The Lyme disease treatment market is projected to grow at a CAGR of 6.2% from 2024 to 2030
03
The vector control market for tick control is expected to reach $2.9 billion globally by 2030 (tick-focused segment within broader vector/vector-borne control)
Interpretation
Market & Adoption Interpretation
From a Market & Adoption perspective, growing demand is clear as the U.S. Lyme diagnostics testing market is forecast to reach $1.8 billion by 2030, while the Lyme treatment market is expected to grow at a 6.2% CAGR from 2024 to 2030 and the global tick control vector control segment could hit $2.9 billion by 2030.
06 · Category
Clinical Practice & Diagnostics1 stats
01
Tiered diagnostic algorithms are intended to reduce false positives compared with relying on single-test results (guideline-based performance rationale)
Interpretation
Clinical Practice & Diagnostics Interpretation
Clinical Practice and Diagnostics relies on tiered diagnostic algorithms to cut down false positives rather than depending on single-test results, reflecting a guideline-driven approach to improving diagnostic accuracy.
07 · Category
Clinical Outcomes & Costs2 stats
01
In a systematic review of antibiotic treatment for early Lyme disease, clinical response was reported in approximately 80%–90% of patients within 1–2 weeks after therapy initiation (review estimate)
02
Lyme disease incurs excess inpatient days of care in the U.S. of about 0.05 days per treated case on average (claims-based estimate)
Interpretation
Clinical Outcomes & Costs Interpretation
For the Clinical Outcomes and Costs category, early Lyme disease treated with antibiotics shows a high clinical response rate of about 80% to 90%, while in the U.S. it still adds roughly 0.05 excess inpatient days of care per treated case on average.
report visual · Comparison
Lyme disease: who’s affected and what care looks like
A small share of places drives most reported cases, while large patient volumes and organ-system involvement highlight broad clinical impact.
~300,000 people in the U.S. visit clinicians annually for Lyme disease concerns (estimate)300,000
11 states accounted for 90% of reported Lyme disease cases in the U.S. in 2017 (reporting concentration by state)
90%
Lyme disease affects multiple organ systems, with neurologic involvement occurring in 15% of cases (clinical manifestati
15%
3.9% of U.S. children had serologic evidence of exposure in a national analysis (age-stratified estimate)
3.9%
source-verifiedcdc.gov · jamanetwork.com · ncbi.nlm.nih.gov · pmc.ncbi.nlm.nih.gov2017
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). Lyme Disease Statistics. Gitnux. https://gitnux.org/lyme-disease-statistics
MLA
Ryan Townsend. "Lyme Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/lyme-disease-statistics.
Chicago
Ryan Townsend. 2026. "Lyme Disease Statistics." Gitnux. https://gitnux.org/lyme-disease-statistics.
Sources & references
37 datasets cited across this report · attribution is report-level
+20 additional datasets cited (not shown individually)